Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab - Wikidata - awgldk - TriplyDB

Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab

Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab

http://www.wikidata.org/entity/Q36930591

about

Phosphodiesterase 4-targeted treatments for autoimmune diseases Angiogenic factors, bladder neuroplasticity and interstitial cystitis-new pathobiological insights Old and new treatment targets in axial spondyloarthritis Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis Updating the OMERACT filter: implications for imaging and soluble biomarkers Bioregulatory systems medicine: an innovative approach to integrating the science of molecular networks, inflammation, and systems biology with the patient's autoregulatory capacity?Update on ankylosing spondylitis: current concepts in pathogenesis.Predicting the outcome of ankylosing spondylitis therapy Calprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis Interleukin-37 is increased in ankylosing spondylitis patients and associated with disease activity.Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN)Systemic inflammatory profile and response to anti-tumor necrosis factor therapy in chronic obstructive pulmonary disease.Osteoimmunology and osteoporosis.Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab.Serum IL-6 and IL-23 Levels and Their Correlation with Angiogenic Cytokines and Disease Activity in Ankylosing Spondylitis, Psoriatic Arthritis, and SAPHO Syndrome.Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis.Association of cytokine and matrix metalloproteinase profiles with disease activity and function in ankylosing spondylitis.Entheses and bones in spondyloarthritis: 2008 Annual Research and Education Meeting of the Spondyloarthritis Research and Therapy Network (SPARTAN).VEGF receptors and neuropilins are expressed in the urothelial and neuronal cells in normal mouse urinary bladder and are upregulated in inflammation.Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment.Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis.Recent advances in neutralizing the IL-6 pathway in arthritis.Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials Screening tests for inflammatory activity: applications in rheumatology.Heavy metal exposure reverses genetic resistance to Chlamydia-induced arthritis.Emerging drugs for axial spondyloarthritis including ankylosing spondylitis.EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice.The ongoing quest for biomarkers in Ankylosing Spondylitis.Pathogenesis of ligaments ossification in spondyloarthritis: insights and doubts.Lessons to be learned from serum biomarkers in psoriasis and IBD - the potential role in SpA.Novel multiplex technology for diagnostic characterization of rheumatoid arthritis.Mucosal inflammation in spondylarthritides: past, present, and future.The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial.In situ analysis of interleukin-6 expression at different sites of zygapophyseal joints from patients with ankylosing spondylitis in comparison to controls.The relationship between inflammation and new bone formation in patients with ankylosing spondylitis.Serum inflammatory biomarkers fail to identify early axial spondyloarthritis: results from the SpondyloArthritis Caught Early (SPACE) cohort What do biomarkers tell us about the pathogenesis of ankylosing spondylitis?Better short-term clinical response to etanercept in Chinese than Caucasian patients with active ankylosing spondylitis.Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial.Association of biomarkers of inflammation, cartilage and bone turnover with gender, disease activity, radiological damage and sacroiliitis by magnetic resonance imaging in patients with early spondyloarthritis.

P2860

Q21245284-078FEEAA-F31E-470D-BDF4-B81C9473603C Q26773577-BC4E455D-CA17-404A-9822-C7082646E610 Q26777906-BA6BB4FA-843F-44A4-93B2-6FB61F97FB5E Q26852081-1BC959F3-C78A-4EF5-BD1B-4802A3AC7761 Q27014889-563AD0CD-3DCE-482E-9C3C-7EA8D2025FC4 Q30661665-5541F4F7-874F-4BDC-BC02-FA7960BF77D9 Q34450732-F48430DD-49E7-485F-A6FB-56ACA1F2B262 Q34905433-EAE7AED6-6A40-44D3-B55F-EB1294B9C160 Q34941693-C649C7DE-65D0-46B9-ACAE-401D3BD5E7CE Q35068107-330A63A1-6E8C-45B9-A021-4C5134392820 Q35605461-DF1D21E8-8193-481C-B904-5D192D51019A Q35779864-7F57E026-07CD-4A7A-9A79-42973379CF43 Q35840701-2E7169D9-BB82-475F-9B14-201A73567DBD Q35896663-129C47FD-5650-4E3A-BBCA-1CF1B6D78997 Q35963238-61271187-CA5B-43DD-AE9B-0DFFBF2C7261 Q36182383-287043AF-64DF-478D-9F0A-1DCC93806A0F Q36246052-47614BE5-94E8-46B3-8D43-7DC834D4D8E8 Q36304001-257D8F98-D60E-45AE-AB2A-2E253D4CA33D Q36807118-FC390B45-FDD1-4352-9EFE-F75F5C7DA44E Q36993320-4456BFBC-2290-42E3-9B6A-A9E120C58B8F Q37020537-05A7C0C3-2C11-4E68-A574-8401DCD8CA13 Q37358099-8C7632DE-B7DC-4615-9F23-EF5C8291BDD6 Q37465459-12DF10F2-83CB-4F08-9CEE-E565674B1517 Q37583658-CBC286B2-610C-4C5C-8E7E-FE638FEC6536 Q37855552-841A955F-A29A-4698-BEB7-79BD11330F37 Q38068578-042D6B48-0373-4C07-B989-35B4F79AA24D Q38402703-07DDC74F-58AB-4012-A87B-4FCBA2D7D79D Q38607774-7143A77C-2411-44B9-9D5B-100AB9B75614 Q38816459-86DCF226-56CA-4121-8904-36DAD5D9F26A Q38972679-30324666-33DC-4ED3-8687-E4F67824C81A Q39186261-C66392F7-0A1F-4F1B-A8D0-638546117954 Q39730329-C303227B-4888-41DE-A667-D528E3657771 Q39925539-4BD38B00-49E5-4C1F-ACDB-7F31EA89ED5E Q41269976-AB77070A-15B5-4455-B7D6-9BCEEA1A5950 Q41396084-0B0D3056-B321-40A0-84E8-B3A4C7877A00 Q42330283-5F6E7E6F-67FC-4BA4-9E38-8EC808982707 Q42580442-40F92F8E-057B-4635-9C0D-EF35C4BAE220 Q42670750-A8334B5D-DD5F-4014-B01E-9E87B45CADF5 Q46231376-DEAB225A-E1AA-4019-9171-B20355D61811 Q46637879-A83C9FAE-4A57-45DB-A0CB-9007C212DFA9

P2860

Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab

http://www.wikidata.org/entity/Q36930591

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Inflammatory biomarkers, disea ...... fter treatment with infliximab

@en

type

label

Inflammatory biomarkers, disea ...... fter treatment with infliximab

@en

prefLabel

Inflammatory biomarkers, disea ...... fter treatment with infliximab

@en

P1433

Q36930591-A751E782-14AA-4B35-BBC5-7522223BEB31

P1476

Q36930591-874372B5-3C72-4194-AFBD-927052A77D09

P2093

Q36930591-26013D8E-95A5-46B5-9C94-0DD6C605627F

Q36930591-3B0E56D9-F3A7-43E2-B885-94BB5B6AB449

Q36930591-3B7EBA53-EB77-4D72-824D-3817E8730D91

Q36930591-611D94BE-BDC7-40EA-8936-99A2B9DA6E61

Q36930591-8E8A5145-A19F-4336-B533-3CA8E00E16E7

Q36930591-9F9921DC-24A2-4F24-8B2D-8C2A0DD04C7A

Q36930591-F5004C76-0D55-474F-965D-CC015A3DF1E2

Q36930591-F7F59F65-8487-481F-A5F9-301BAE04710D

P2860

Q36930591-065BE51F-C7C4-4E11-BAAE-8F2087811807

Q36930591-18F8BD64-B1D1-4914-9515-9270C43667D0

Q36930591-1FB6A7C3-5DE1-4F42-A173-474AB0083F70

Q36930591-24248D3E-F4F1-4139-81CA-C377DA2A1FCF

Q36930591-2CBAC4D2-54FA-4C10-8105-5B9FDE6ABF71

Q36930591-38950EB1-DEE0-435D-B7E9-0D156F3D9993

Q36930591-52EA9152-94A5-4B8E-B65B-9963BBA780FF

Q36930591-5A35B608-A59E-4BB8-9200-A33628BCC704

Q36930591-5D11E0B3-8D1F-49A3-A385-696A3D865F1F

Q36930591-62D80E2E-E823-4752-A661-3D0D04EA2B6E

P304

Q36930591-F7EDACDC-BB2B-43E3-83AC-8E614B080CEF

P31

Q36930591-58538219-9256-4CEC-94EA-0F8014340721

P356

Q36930591-78FCC1C1-52E8-475D-A559-92FBC98C9AFE

P407

Q36930591-C5CCD409-7F2F-4809-A201-D33E270B30DB

P433

Q36930591-9CAF5A00-AC65-4F92-A020-DBAD4FAE7229

P478

Q36930591-CDD940FB-17E7-419A-B4DA-C444134FE42B

P577

Q36930591-4BE2D910-6B09-4551-9F21-0F4CF0340241

P5875

Q36930591-DDF6C4C3-D4BD-41C3-8875-D483E2952650

P698

Q36930591-F3227565-3B00-4E65-ABA4-354CE3618C6B

P921

Q36930591-DB4958AF-7772-4D0C-9D3F-4A6B7202BD7E

P932

Q36930591-7F20116E-053E-4799-BBC0-C79B6E26DCC2

P356

ARD.2007.071605

P1433

Annals of the Rheumatic Diseases

P1476

Inflammatory biomarkers, disea ...... fter treatment with infliximab

@en

P2093

Baker D

http://www.w3.org/2001/XMLSchema#string

Braun J

http://www.w3.org/2001/XMLSchema#string

Gathany T

http://www.w3.org/2001/XMLSchema#string

Han J

http://www.w3.org/2001/XMLSchema#string

Marini JC

http://www.w3.org/2001/XMLSchema#string

Visvanathan S

http://www.w3.org/2001/XMLSchema#string

Wagner C

http://www.w3.org/2001/XMLSchema#string

van der Heijde D

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index

Antigen induced arthritis (AIA) can be transferred by bone marrow transplantation: evidence that interleukin 6 is essential for induction of AIA.

Arginine-rich anti-vascular endothelial growth factor (anti-VEGF) hexapeptide inhibits collagen-induced arthritis and VEGF-stimulated productions of TNF-alpha and IL-6 by human monocytes.

Interleukin-6, acute phase reactants and clinical status in ankylosing spondylitis

Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis.

IL-6 in autoimmune disease and chronic inflammatory proliferative disease.

Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes.

Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis.

Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.

P304

511-517

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ARD.2007.071605

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

67

http://www.w3.org/2001/XMLSchema#string

P577

2007-07-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6193198

http://www.w3.org/2001/XMLSchema#string

P698

17644552

http://www.w3.org/2001/XMLSchema#string

P921

P932

2564765

http://www.w3.org/2001/XMLSchema#string